Skip to main
NKTX

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is positioned favorably in the biopharmaceutical sector by leveraging its unique NK expansion platform technology and proprietary cell engineering to enhance the efficacy and availability of off-the-shelf NK cell therapies. The decision to reintegrate standardized lymphodepletion with fludarabine has significantly improved patient enrollment, showcasing the company's potential to successfully advance its clinical trials. Additionally, Nkarta represents an appealing investment opportunity within an emerging therapeutic category that addresses key limitations of current cancer treatments, particularly those related to autologous CAR-T therapies.

Bears say

Nkarta Inc. is experiencing a significant reduction in its operating expenses, with research and development spending declining by 14% sequentially and selling, general, and administrative expenses dropping by 48%, which may signal financial distress or efficiency issues. The upcoming protocol amendment related to the NKX019 lymphodepletion regimen is raising concerns about the ability to draw definitive conclusions from the company's initial disclosures due to the anticipated limited patient data, potentially impeding progress in clinical trials. Furthermore, the choice to delay the release of key preliminary data until a more comprehensive presentation in FY26 reflects a cautious approach that may reflect the inconclusiveness of prior results, contributing to an overall negative sentiment regarding Nkarta's stock outlook.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.